Northstar pares ops; homes in on depression
This article was originally published in Clinica
Neuromodulation technology company Northstar Neuroscience said it has decided to put its stroke clinical programme on hold and instead, channel its efforts exclusively on its treatment-resistant depression (TRD) research.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.